MYND Life Sciences (XCNQ:MYND) Change In Payables And Accrued Expense : C$1.07 Mil (TTM As of Jul. 2024)

View and export this data going back to 2021. Start your Free Trial

What is MYND Life Sciences Change In Payables And Accrued Expense?

MYND Life Sciences's Change In Payables And Accrued Expense for the quarter that ended in Jul. 2024 was C$0.33 Mil. It means MYND Life Sciences's Accounts Payable & Accrued Expense increased by C$0.33 Mil from Apr. 2024 to Jul. 2024 .

MYND Life Sciences's Change In Payables And Accrued Expense for the fiscal year that ended in Oct. 2023 was C$1.23 Mil. It means MYND Life Sciences's Accounts Payable & Accrued Expense increased by C$1.23 Mil from Oct. 2022 to Oct. 2023 .

MYND Life Sciences Change In Payables And Accrued Expense Historical Data

The historical data trend for MYND Life Sciences's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MYND Life Sciences Change In Payables And Accrued Expense Chart

MYND Life Sciences Annual Data

Trend

Oct21

Oct22

Oct23

Change In Payables And Accrued Expense

0.23

1.32

1.23

MYND Life Sciences Quarterly Data
	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial										0.25	0.10	0.31	0.33	0.33

MYND Life Sciences Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$1.07 Mil.

MYND Life Sciences Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of MYND Life Sciences's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

MYND Life Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MYND Life Sciences Inc (XCNQ:MYND) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

MYNDF:USA

Address

105-2248 Elgin Avenue, Port Coquitlam, BC, CAN, V3C 2B2

Website

https://www.myndsciences.com

MYND Life Sciences Inc is a medical biotech drug research and development company. The company is focused on neuro pharmaceutical and novel drug development, diagnostics, and vaccines and is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other (bio)pharmaceutical companies by different molecular concepts for the applications of psilocybin analogs for overcoming diseases.